학술논문
Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
Document Type
Article
Author
Weller, Johannes; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Hau, Peter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Bähr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Brehmer, Stefanie; Bullinger, Lars; Galldiks, Norbert; Schaub, Christina; Kebir, Sied; Stummer, Walter; Simon, Matthias; Fimmers, Rolf; Coch, Christoph; Glas, Martin; Herrlinger, Ulrich ; Schäfer, Niklas
Source
In The Lancet Oncology October 2019 20(10):1444-1453
Subject
Language
ISSN
1470-2045